Abstract | OBJECTIVE: The purpose of this trial was to study the use of terazosin in nonbacterial prostatitis/prostatodynia, and to evaluate a new symptom score sheet for this disease. METHODS: RESULTS: Nineteen patients (76%) responded to one month's therapy, with 11 (58%) remaining asymptomatic three months later. The symptom score index, as measured by Cronbach's alpha measure of index reliability, was excellent at 0.78 and logistic regression analysis demonstrated each prostatitis question to have independent validity (P < 0.001) but not to the extent of the combined score. CONCLUSIONS:
Terazosin appears effective in treating patients with nonbacterial prostatitis/prostatodynia. This new symptom score is one way to evaluate and track patients with this disease. A randomized, placebo-controlled clinical trial has been initiated to study this.
|
Authors | D E Neal Jr, T D Moon |
Journal | Urology
(Urology)
Vol. 43
Issue 4
Pg. 460-5
(Apr 1994)
ISSN: 0090-4295 [Print] United States |
PMID | 7512296
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Adrenergic alpha-Antagonists
- Terazosin
- Prazosin
|
Topics |
- Adrenergic alpha-Antagonists
(therapeutic use)
- Adult
- Humans
- Logistic Models
- Male
- Middle Aged
- Pain
(drug therapy, etiology)
- Pain Measurement
- Prazosin
(analogs & derivatives, therapeutic use)
- Prospective Studies
- Prostatic Diseases
(drug therapy)
- Prostatic Hyperplasia
(complications, diagnosis, physiopathology)
- Prostatitis
(complications, diagnosis, drug therapy, physiopathology)
- Surveys and Questionnaires
- Urodynamics
|